Jeffrey L. Browning, PhD
Research Professor
Boston University School of Medicine
Dept of Microbiology

PhD, University of Wisconsin Madison

My interests focus on understanding how the immune system interacts with stromal elements to form the specialized structures that orchestrate immunological encounters in lymphoid organs. On a different plane, the barriers to effective quantitation of disease are formidable in some autoimmune diseases especially those with considerable unmet need such as lupus and scleroderma. I am interested in bringing new views onto the human immune system to improve clinical studies.

Mesenchymal cell differentiation pathways are intimately interwoven with pathological processes e.g. compromised vascular integrity, aberrant tissue remodeling and fibrosis and tumor-stromal interactions. In lymphoid organs, the lymphotoxin pathway, a TNF family member, is one mechanism by which both innate and adaptive lymphoid cells communicate with their stromal microenvironments. The maintenance of a differentiated follicular dendritic cell network to scaffold the B cell follicle is a well-studied example of this communication. More recently, it is becoming clearer that another network, the fibroblastoid reticular cell network, is a differentiated form of mural cells, e.g. pericytes or vascular smooth muscle cells. The precise role of the lymphotoxin pathway in controlling this structure is an area of investigation. As lymph nodes can undergo massive expansion in response to danger following by involution, they form an intriguing model of physiological tissue remodeling. One-approach we are taking addresses whether the control of these cells in lymphoid tissue provides lessons that are applicable to non-lymphoid disease settings such as scleroderma skin and lung.

The ability to assess drug function in complex immunological diseases can be seriously limited by the quality of the metrics used to quantitate disease. One focus is on a potential new blood test for salivary gland function in Sjogren’s disease. Additionally, there is interest in understanding the origin of the blood RNA interferon signature commonly observed in autoimmune diseases and how this signature may provide insight into the ongoing pathology in lupus, Sjogren’s and scleroderma. The overarching goal is to understand how readily measureable blood parameters such as chemokine levels or various RNA signatures can report on the activity in lymph nodes and the spleen and hence inform on whether the immune system is flaring or smoldering.

Research Professor
Boston University School of Medicine
Rheumatology (Arthritis)

Fibroblast activation foretells leukocyte infiltration and autoimmune attack on non-lymphoid organs
09/01/2018 - 08/31/2019 (PI)
The American Association of Immunologists

Modulation of DCLK1 and Related Pathways as Targets in Lupus Nephritis
08/21/2017 - 08/20/2019 (PI)
F. Hoffmann-La Roche, Ltd.

Biomarker based prediction models for response to treatment in systemic sclerosis related interstitial lung disease
09/15/2016 - 09/14/2018 (PI)
University of Texas Health Science Center, Houston DOD Army Med Resrch

Yr Title Project-Sub Proj Pubs
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Ho JD, Chung HJ, Ms Barron A, Ho DA, Sahni D, Browning JL, Bhawan J. Extensive CD34-to-CD90 Fibroblast Transition Defines Regions of Cutaneous Reparative, Hypertrophic, and Keloidal Scarring. Am J Dermatopathol. 2019 Jan; 41(1):16-28.View Related Profiles. PMID: 30320623.
  2. Barron AMS, Mantero JC, Ho JD, Nazari B, Horback KL, Bhawan J, Lafyatis R, Lam C, Browning JL. Perivascular Adventitial Fibroblast Specialization Accompanies T Cell Retention in the Inflamed Human Dermis. J Immunol. 2019 Jan 01; 202(1):56-68.View Related Profiles. PMID: 30510068.
  3. St Clair EW, Baer AN, Wei C, Noaiseh G, Parke A, Coca A, Utset TO, Genovese MC, Wallace DJ, McNamara J, Boyle K, Keyes-Elstein L, Browning JL, Franchimont N, Smith K, Guthridge JM, Sanz I, James JA. Clinical Efficacy and Safety of Baminercept, a Lymphotoxin ß Receptor Fusion Protein, in Primary Sjögren's Syndrome: Results From a Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Arthritis Rheumatol. 2018 09; 70(9):1470-1480. PMID: 29604186.
  4. Grzegorzewska AP, Seta F, Han R, Czajka CA, Makino K, Stawski L, Isenberg JS, Browning JL, Trojanowska M. Dimethyl Fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Sci Rep. 2017 02 02; 7:41605.View Related Profiles. PMID: 28150703; DOI: 10.1038/srep41605;.
  5. Gardet A, Chou WC, Reynolds TL, Velez DB, Fu K, Czerkowicz JM, Bajko J, Ranger AM, Allaire N, Kerns HM, Ryan S, Legault HM, Dunstan RW, Lafyatis R, Lukashev M, Viney JL, Browning JL, Rabah D. Pristane-Accelerated Autoimmune Disease in (SWR X NZB) F1 Mice Leads to Prominent Tubulointerstitial Inflammation and Human Lupus Nephritis-Like Fibrosis. PLoS One. 2016; 11(10):e0164423.View Related Profiles. PMID: 27760209; DOI: 10.1371/journal.pone.0164423;.
  6. Chia JJ, Zhu T, Chyou S, Dasoveanu DC, Carballo C, Tian S, Magro CM, Rodeo S, Spiera RF, Ruddle NH, McGraw TE, Browning JL, Lafyatis R, Gordon JK, Lu TT. Dendritic cells maintain dermal adipose-derived stromal cells in skin fibrosis. J Clin Invest. 2016 Nov 01; 126(11):4331-4345.View Related Profiles. PMID: 27721238; DOI: 10.1172/JCI85740;.
  7. Nazari B, Rice LM, Stifano G, Barron AM, Wang YM, Korndorf T, Lee J, Bhawan J, Lafyatis R, Browning JL. Altered Dermal Fibroblasts in Systemic Sclerosis Display Podoplanin and CD90. Am J Pathol. 2016 Oct; 186(10):2650-64.View Related Profiles. PMID: 27565038; DOI: 10.1016/j.ajpath.2016.06.020;.
  8. Mejías-Luque R, Zöller J, Anderl F, Loew-Gil E, Vieth M, Adler T, Engler DB, Urban S, Browning JL, Müller A, Gerhard M, Heikenwalder M. Lymphotoxin ß receptor signalling executes Helicobacter pylori-driven gastric inflammation in a T4SS-dependent manner. Gut. 2017 Aug; 66(8):1369-1381. PMID: 27196595; DOI: 10.1136/gutjnl-2015-310783;.
  9. Seleznik G, Seeger H, Bauer J, Fu K, Czerkowicz J, Papandile A, Poreci U, Rabah D, Ranger A, Cohen CD, Lindenmeyer M, Chen J, Edenhofer I, Anders HJ, Lech M, Wüthrich RP, Ruddle NH, Moeller MJ, Kozakowski N, Regele H, Browning JL, Heikenwalder M, Segerer S. The lymphotoxin ß receptor is a potential therapeutic target in renal inflammation. Kidney Int. 2016 Jan; 89(1):113-26. PMID: 26398497; DOI: 10.1038/ki.2015.280;.
  10. Rice LM, Ziemek J, Stratton EA, McLaughlin SR, Padilla CM, Mathes AL, Christmann RB, Stifano G, Browning JL, Whitfield ML, Spiera RF, Gordon JK, Simms RW, Zhang Y, Lafyatis R. A longitudinal biomarker for the extent of skin disease in patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 2015 Nov; 67(11):3004-15.View Related Profiles. PMID: 26240058; DOI: 10.1002/art.39287;.
Showing 10 of 120 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 120 publications over 32 distinct years, with a maximum of 9 publications in 1997

In addition to these self-described keywords below, a list of MeSH based concepts is available here.

immune system

Available to Mentor as: (Review Mentor Role Definitions):
  • Advisor
  • Career Mentor
  • Co-Mentor or Peer Mentor
  • Project Mentor
  • Research / Scholarly Mentor
Contact for Mentoring:

72 E. Concord St Instructional (L)
Boston MA 02118
Google Map

Browning's Networks
Click the "See All" links for more information and interactive visualizations
Similar People
Same Department